Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
We compared seminal plasma pharmacokinetic data for the investigational amprenavir prodrug GW433908 with those for amprenavir and an amprenavir-ritonavir combination regimen. All 3 regimens resulted in detectable blood plasma and seminal plasma concentrations of amprenavir. The majority of these concentrations were greater than the plasma protein-corrected 50% inhibitory concentration for wild-type human immunodeficiency virus type 1.
Chaudry
Naumann I
NI
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Eron
Joseph J
JJ
Naderer
Odin J
OJ
Pereira
Arlene S
AS
Wire
M B
MB
Fiscus
Susan A
SA
Kashuba
Angela D M
AD
D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood*; D002219:Carbamates; D002626:Chemistry, Pharmaceutical; D005663:Furans; D015658:HIV Infections / Q000097:blood*; D017320:HIV Protease Inhibitors / Q000097:blood; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D010755:Organophosphates; D011355:Prodrugs / Q000493:pharmacokinetics; D019438:Ritonavir / Q000097:blood; D012661:Semen / Q000378:metabolism; D013449:Sulfonamides / Q000097:blood*
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D011355:Prodrugs; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir; C426859:fosamprenavir